The only growth hormone peptide with FDA approval. Specifically targets visceral abdominal fat — the "menopause belly" that is the #1 body composition complaint among perimenopausal and menopausal women.
Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to produce and release growth hormone in a physiological, pulsatile pattern. Unlike exogenous GH, tesamorelin works with your body's natural feedback mechanisms. The resulting GH elevation preferentially targets visceral adipose tissue (VAT) — the deep abdominal fat associated with metabolic disease.
Visceral belly fat is the #1 physical complaint of menopausal women. As estrogen declines, fat distribution shifts from subcutaneous (hips/thighs) to visceral (abdomen) — a pattern associated with increased cardiovascular and metabolic risk. Tesamorelin is the only GH peptide with FDA approval (for HIV lipodystrophy), giving it the strongest clinical evidence profile. Multiple integrative clinics specifically recommend tesamorelin over CJC-1295/Ipamorelin when visceral fat is the primary concern.
Common side effects include injection site reactions (erythema, pruritus), arthralgia, and peripheral edema. Fluid retention and carpal tunnel-like symptoms may occur due to GH elevation. Contraindicated in pregnancy and in patients with active malignancy.
This peptide is part of our Weight Management hub — explore all peptides for this use case.
They work through completely different mechanisms. Tesamorelin specifically targets visceral abdominal fat via growth hormone pathways, while semaglutide reduces overall body weight via appetite suppression. For specifically targeting visceral belly fat, tesamorelin is more precise. Some practitioners use both.
Mild fluid retention and peripheral edema are possible side effects, as with any therapy that increases growth hormone levels. These effects are typically dose-dependent and manageable. Tesamorelin causes less fluid retention than exogenous GH because it works through natural pulsatile release.
Clinical trials showed significant visceral fat reduction within 26 weeks of treatment. Visible changes in abdominal circumference are typically noticed within 8-12 weeks.
Medical Disclaimer: This profile is for educational purposes only. It is not medical advice, a treatment recommendation, or a prescription guide. Always consult a licensed healthcare provider before starting any peptide therapy. Evidence ratings reflect the current state of published research and may change as new data emerges.
Affiliate Disclosure: Vendor links above are affiliate partnerships. FemPeptides may earn a commission on purchases. This does not influence our editorial content or evidence ratings. Full disclosure →
Take our 60-second quiz for a personalized recommendation based on your goals and life stage.
Find Your Peptide →